Treatment
This study consists of the following treatment: Nab-paclitaxel + bevacizumab + relacorilant.
- Nab-Paclitaxel: intravenous administration, day 1, 8, 15 of a 4-week cycle
- Bevacizumab: intravenous administration, day 1, 15 of a 4-week cycle
- Relacorilant: oral medication
Treatment duration
The treatments can continue until disease progression, unacceptable toxicities or until you decide to stop.
Contact
To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.